These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 12907822

  • 1. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
    Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S.
    Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
    [Abstract] [Full Text] [Related]

  • 2. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I, Janik P, Sokołowska B, Kwiecinski H.
    Eur J Neurol; 2010 Feb 02; 17(2):226-31. PubMed ID: 19796283
    [Abstract] [Full Text] [Related]

  • 4. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke.
    Rosell A, Alvarez-Sabín J, Arenillas JF, Rovira A, Delgado P, Fernández-Cadenas I, Penalba A, Molina CA, Montaner J.
    Stroke; 2005 Jul 02; 36(7):1415-20. PubMed ID: 15947272
    [Abstract] [Full Text] [Related]

  • 5. Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism.
    Mühl D, Ghosh S, Uzuelli JA, Lantos J, Tanus-Santos JE.
    Thromb Res; 2010 Jun 02; 125(6):549-53. PubMed ID: 20307903
    [Abstract] [Full Text] [Related]

  • 6. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S, Buerger K, Hampel H, Beal MF.
    Int Psychogeriatr; 2008 Feb 02; 20(1):67-76. PubMed ID: 17697439
    [Abstract] [Full Text] [Related]

  • 7. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D, Hrynyschyn K, Pallua N.
    Plast Reconstr Surg; 2003 Oct 02; 112(5):1279-86. PubMed ID: 14504511
    [Abstract] [Full Text] [Related]

  • 8. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D, Nagy B, Woth G, Falusi B, Bogár L, Weber G, Lantos J.
    J Crit Care; 2011 Dec 02; 26(6):550-5. PubMed ID: 21530151
    [Abstract] [Full Text] [Related]

  • 9. The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower Limb Endovascular Interventions for Peripheral Arterial Disease.
    Giagtzidis IT, Kadoglou NP, Mantas G, Spathis A, Papazoglou KO, Karakitsos P, Liapis CD, Karkos CD.
    Ann Vasc Surg; 2017 Aug 02; 43():188-196. PubMed ID: 28288884
    [Abstract] [Full Text] [Related]

  • 10. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes.
    Vukasovic I, Tesija-Kuna A, Topic E, Supanc V, Demarin V, Petrovcic M.
    Clin Chem Lab Med; 2006 Aug 02; 44(4):428-34. PubMed ID: 16599837
    [Abstract] [Full Text] [Related]

  • 11. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    J Rheumatol; 2004 Feb 02; 31(2):238-42. PubMed ID: 14760791
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z, Zatloukal J, Kriegova E, Kolek V, Petrek M.
    Respirology; 2012 Aug 02; 17(6):1006-12. PubMed ID: 22591289
    [Abstract] [Full Text] [Related]

  • 13. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ, Lacchini R, Belo VA, Nobre YT, Tucci S, Martins AC, Tanus-Santos JE.
    Int J Impot Res; 2012 Aug 02; 24(1):38-43. PubMed ID: 21918531
    [Abstract] [Full Text] [Related]

  • 14. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
    Krawczuk-Rybak M, Kuźmicz M, Mroczko B, Szmitkowski M.
    Pol Merkur Lekarski; 2010 Jul 02; 29(169):14-8. PubMed ID: 20712241
    [Abstract] [Full Text] [Related]

  • 15. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B, Głowińska B, Urban M, Peczyńska J.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Jul 02; 12(3):184-9. PubMed ID: 17020653
    [Abstract] [Full Text] [Related]

  • 16. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
    Muhammad S, Planz O, Schwaninger M.
    Cerebrovasc Dis Extra; 2016 Jul 02; 6(2):50-9. PubMed ID: 27560521
    [Abstract] [Full Text] [Related]

  • 17. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.
    Anticancer Res; 2000 Jul 02; 20(2B):1311-6. PubMed ID: 10810441
    [Abstract] [Full Text] [Related]

  • 18. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP, Molenaar IQ, Verspaget HW, Veldman MG, Palareti G, Legnani C, Moolenburgh SE, Terpstra OT, Lamers CB, van Hoek B, Porte RJ.
    Thromb Haemost; 2004 Mar 02; 91(3):506-13. PubMed ID: 14983226
    [Abstract] [Full Text] [Related]

  • 19. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT.
    Rheumatology (Oxford); 2006 Apr 02; 45(4):414-20. PubMed ID: 16287916
    [Abstract] [Full Text] [Related]

  • 20. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women.
    Lewandowski KC, Komorowski J, Mikhalidis DP, Bienkiewicz M, Tan BK, O'Callaghan CJ, Lewinski A, Prelevic G, Randeva HS.
    J Clin Endocrinol Metab; 2006 Aug 02; 91(8):3123-30. PubMed ID: 16705077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.